Tech Company Financing Transactions
Retrophin Funding Round
Retrophin secured a $4 million Series A venture capital round on 5/8/2012. Investors included MSMB Capital and private investors.
Transaction Overview
Company Name
Announced On
5/8/2012
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Series A
Investors
MSMB Capital (Martin Shkreli)
Proceeds Purpose
The company intends to invest the proceeds from the Series A financing to advance its pipeline of novel rare-disease drug candidates, including a proof-of-concept study of RE-021 (a dual acting receptor antagonist of Angiotensin and Endothelin receptors) in Focal Segmental Glomerulosclerosis (FSGS) scheduled to begin enrolling patients during the second quarter of this year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3721 Valley Centre Dr. 200
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Overview
Retrophin, LLC is a privately-held New York-based, biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Aselage
Chief Financial Officer
Laura Clague
Chief Medical Officer
Noah Rosenberg
Chief Operating Officer
Neil McFarlane
VP - General Counsel
Elizabeth Reed
VP - R & D
William Rote
Browse more venture capital transactions:
Prev: 5/8/2012: Cybera venture capital transaction
Next: 5/8/2012: TrueVision Systems venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs